Email this article 
Hide
Show all
Guideline
SASCM guideline for daptomycin use in South Africa – 2017 update
Southern African Journal of Infectious Diseases | Vol 32, No 2 | a58 |
DOI: https://doi.org/10.4102/sajid.v32i2.58
| © 2019 Warren Lowman, Jennifer Coetzee, Olga Perovic
| This work is licensed under CC Attribution 4.0
Submitted: 14 May 2019 | Published: 01 July 2017
Submitted: 14 May 2019 | Published: 01 July 2017
About the author(s)
Warren Lowman, Vermaak and Partners Pathologists, Pretoria, South Africa; Ampath, National Reference Laboratory, Microbiology, Pretoria, South Africa;Department of Clinical Microbiology and Infectious Diseases, University of Witwatersrand, Johannesburg, South AfricaJennifer Coetzee, Ampath, National Reference Laboratory, Microbiology, Pretoria, South Africa
Olga Perovic, National Institute for Communicable Diseases, Centre for Tropical, Opportunistic and Hospital Infections, Johannesburg, South Africa; Department of Clinical Microbiology and Infectious Diseases, University of Witwatersrand, Johannesburg, South Africa
Full Text:
PDF (205KB)Abstract
Daptomycin is currently registered for use in treatment of complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bacteraemia. The role of daptomycin in treatment of severe Gram-positive infections needs to be considered outside of these specific and rigid indications. Based on surveillance data, supporting literature and within the context of antimicrobial stewardship, the South African Society for Clinical Microbiology (SASCM) provides recommendations for appropriate use of daptomycin. These recommendations were formulated by members of the National Antimicrobial Committee (NAC), a
sub-committee of SASCM, following consultation and review of the relevant literature.
Keywords
antimicrobial stewardship; antimicrobial therapy; daptomycin; Gram-positive infections
Metrics
Total abstract views: 2810Total article views: 1527